Atherosclerotic renal artery stenosis (ARAS) remains the leading cause of renovascular disease. ARAS causes hypertension, loss of renal function, and cardiovascular complications.
Treatment by means of percutaneous transluminal renal artery stenting (PTRAS) is disappointing in preserving renal function and preventing cardiovascular events.
Microvascular remodelling (rarefaction) is an important pathologic alteration in the stenotic kidney.
PTRAS cannot repair the pre-existed intrarenal damage.
Nephrospec joins the Medispec line of superior, non-invasive, deep penetration Shock Wave Therapy systems, ensuring a high success rate within a relatively short time frame. It is compact and mobile, making it easy to store and move from room to room. The device is Multi-Purpose, and may be used for treatment of ED, CPPS, as well as other urology, vascular and orthopaedics disorders, all in one unit.